Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-09-29
1997-03-04
Springer, David B.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514383, 514397, 548251, 5483147, 5482664, C07D40312, C07D40114, A61K 3141, A61K 31415
Patent
active
056079575
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to a class of substituted imidazole, triazole and tetrazole derivatives which act on 5-hydroxytryptamine (5-HT) receptors, being selective agonists of so-called "5-HT.sub.1 -like" receptors. They are therefore useful in the treatment of clinical conditions for which a selective agonist of these receptors is indicated.
5-HT.sub.1 -like receptor agonists which exhibit selective vasoconstrictor activity have recently been described as being of use in the treatment of migraine (see, for example, A. Doenicke et al., The Lancet, 1988, Vol. 1, 1309-11). The compounds of the present invention, being selective 5-HT.sub.1 -like receptor agonists, are accordingly of particular use in the treatment of migraine and associated conditions, e.g. cluster headache, chronic paroxysmal hemicrania, headache associated with vascular disorders, tension headache and paediatric migraine.
The present invention provides a compound of formula I, or a salt or prodrug thereof: ##STR1## wherein the broken circle represents two non-adjacent double bonds in any position in the five-membered ring; represent carbon provided that, when two of W, X, Y and Z represent nitrogen and the remainder represent carbon, then the said nitrogen atoms are in non-adjacent positions within the five-membered ring;
A.sup.1 represents hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, --OR.sup.x, --SR.sup.x, --NR.sup.x R.sup.y, --NR.sup.x COR.sup.y, --NR.sup.x CO.sub.2 R.sup.y, --NR.sup.x SO.sub.2 R.sup.y, or --NR.sup.z CTNR.sup.x R.sup.y ; Z represent nitrogen; or, when two or three of W, X, Y and Z represent nitrogen and the remainder represent carbon, A.sup.2 represents hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, --OR.sup.x, --SR.sup.x, --NR.sup.x R.sup.y, --NR.sup.x COR.sub.y, --NR.sup.x CO.sub.2 R.sup.y, --NR.sup.x SO.sub.2 R.sup.y, or --NR.sup.2 CTNR.sup.x R.sup.y ; from 1 to 4 carbon atoms; ##STR2## U represents nitrogen or C--R.sup.2 ; B represents oxygen, sulphur or N--R.sup.3 ; formula ##STR3## in which the broken line represents an optional chemical bond; R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 independently represent hydrogen or C.sub.1-6 alkyl; heterocyclic group, or R.sup.x and R.sup.y together represent a C.sub.2-6 alkylene group; group.
For use in medicine, the salts of the compounds of formula I will be non-toxic pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.
The term "hydrocarbon" as used herein includes straight-chained, branched and cyclic groups containing up to 18 carbon atoms, suitably up to 15 carbon atoms, and conveniently up to 12 carbon atoms. Suitable hydrocarbon groups include C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl(C.sub.1-6) alkyl, aryl and aryl(C.sub.1-6) alkyl.
The expression "a heterocyclic group" as used herein includes cyclic groups containing up to 18 carbon atoms and at least one heteroatom preferably selected from oxygen, nitrogen and sulphur. The heterocyclic group suitably contains up to 15 carbon atoms and conveniently up to 12 carbon atoms, and
REFERENCES:
patent: 5225431 (1993-06-01), Robertson et al.
patent: 5298520 (1994-03-01), Baker et al.
Castro Pineiro Jose L.
Matassa Victor G.
Merck Sharp & Dohme Ltd.
North Robert J.
Springer David B.
Winokur Melvin
LandOfFree
Imidazole, triazole and tetrazole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazole, triazole and tetrazole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazole, triazole and tetrazole derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2146235